EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology
Published inAnnals of the rheumatic diseases, vol. 69, no. 9, p. 1596-1602
Publication date2010
Abstract
Keywords
- Adverse Drug Reaction Reporting Systems/*organization & administration
- Antirheumatic Agents/*adverse effects/therapeutic use
- Biological Agents/*adverse effects/therapeutic use
- Epidemiologic Methods
- Europe
- Humans
- Patient Selection
- Registries/*standards
- Rheumatic Diseases/*drug therapy
- Treatment Outcome
Affiliation entities
Research groups
Citation (ISO format)
DIXON, William G. et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. In: Annals of the rheumatic diseases, 2010, vol. 69, n° 9, p. 1596–1602. doi: 10.1136/ard.2009.125526
Main files (1)
Article
Identifiers
- PID : unige:20903
- DOI : 10.1136/ard.2009.125526
- PMID : 20525843
Additional URL for this publicationhttp://ard.bmj.com/content/69/9/1596.full.pdf
Journal ISSN0003-4967